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Abstract
Fusion between the viral and target cell membranes is an obligatory step for the infectivity of all enveloped virus, and
blocking this process is a clinically validated therapeutic strategy. Viral fusion is driven by specialized proteins which,
although specific to each virus, act through a common mechanism, the formation of a complex between two heptad repeat
(HR) regions. The HR regions are initially separated in an intermediate termed ‘‘prehairpin’’, which bridges the viral and cell
membranes, and then fold onto each other to form a 6-helical bundle (6HB), driving the two membranes to fuse. HR-derived
peptides can inhibit viral infectivity by binding to the prehairpin intermediate and preventing its transition to the 6HB. The
antiviral activity of HR-derived peptides differs considerably among enveloped viruses. For weak inhibitors, potency can be
increased by peptide engineering strategies, but sequence-specific optimization is time-consuming. In seeking ways to
increase potency without changing the native sequence, we previously reported that attachment to the HR peptide of a
cholesterol group (’’cholesterol-tagging’’) dramatically increases its antiviral potency, and simultaneously increases its half-
life in vivo. We show here that antiviral potency may be increased by combining cholesterol-tagging with dimerization of
the HR-derived sequence, using as examples human parainfluenza virus, Nipah virus, and HIV-1. Together, cholesterol-
tagging and dimerization may represent strategies to boost HR peptide potency to levels that in some cases may be
compatible with in vivo use, possibly contributing to emergency responses to outbreaks of existing or novel viruses.
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Introduction
Fusion between the viral and the target cell membrane is an
obligatory step for the infectivity of all enveloped viruses. The
development of compounds – peptides in particular – which block
this process is a well-established therapeutic strategy [1] that has
been clinically validated for the retrovirus human immunodefi-
ciency virus type 1 (HIV-1) with the development of the peptide
fusion inhibitor enfuvirtide (FuzeonH, also known as T20) [2].
Viral fusion is driven by specialized proteins which, although
specific to each virus, act through a common mechanism. In
particular the more prevalent ‘‘class I’’ fusion proteins harbor two
heptad repeat (HR) regions which are central to the process, the
first one in the N-terminal region, adjacent to the fusion peptide
(HRN), and the second one in the C-terminal region, immediately
preceding the transmembrane domain (HRC). The currently
accepted model stipulates that once fusion is initiated by the
binding of the envelope glycoprotein (gp) to its cellular receptor,
the HRN and HRC regions become separated in the so-called
prehairpin intermediate, which bridges the viral and cell
membranes; in the prehairpin structure, HRN forms a trimeric
coiled-coil. Folding of the HRC onto the HRN trimer leads to the
formation of a 6-helical bundle (6HB), and in this process the two
membranes are driven in close apposition, ultimately resulting in
their fusion, as reviewed in [1]. In this view, inhibitors that bind to
the prehairpin intermediate and prevent its transition to the 6HB
inhibit viral entry. This is the case for enfuvirtide, which spans part
of the HRC region of the fusogenic protein gp41 of HIV-1 [2].
The same mechanism of inhibition applies to peptides derived
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[3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19].
The characteristic sequence pattern of the heptad repeats,
which drive formation of coiled coils, provides an important
advantage for the development of peptide-based antivirals:
putative HRN and HRC peptides in viral fusion proteins can be
easily identified directly from genomic information, through
computer programs like LearnCoil [20] or MultiCoil [21,22].
Indeed, for the emerging coronavirus that in recent years caused
the SARS outbreak [23], identification of HRN and HRC regions
[24] and development of peptide inhibitors [17,19] preceded the
determination of the structure of the fusion protein [25,26,27,28].
Therefore, in addition to being a viable strategy for known
viruses, inhibition of viral fusion offers the opportunity for a rapid
response to emerging viral pathogens, opening the possibility to
develop a specific antiviral in very short timeframe.
However, the potency of HR-derived peptides differs consider-
ably among enveloped viruses, with HIV being a particularly
favorable case. The reasons for this difference are not fully
established, although a major factor is represented by fusion
kinetics. Indeed, viruses with a slower transition through the
hairpin intermediate offer a longer window of opportunity for
peptide inhibitors that, accordingly, show greater potency
[29,30,31].
Several peptide engineering strategies have been successfully
applied to increase the potency of peptide fusion inhibitors
[8,32,33,34,35,36,37]. However, they all require sequence-specific
modifications, a relatively time-consuming optimization process.
We have taken a different approach, seeking ways to increase
antiviral activity without the need to change the native HR-
derived sequence.
To this end, we have previously reported that by attaching a
cholesterol group to a peptide fusion inhibitor (‘‘cholesterol-
tagging’’) we can dramatically increase its antiviral potency [38].
Cholesterol-tagging of C34, a peptide from the HRC domain of
HIV-1 gp41, produced an inhibitor (C34-chol) that, depending on
the viral strain tested, is 25- to 100-fold more potent than
unconjugated C34, and 50- to 400-fold more potent than the
clinical drug enfuvirtide [38].
We showed that this is the result of selectively enriching the
peptide in the membrane, where viral fusion occurs [39,40,41,42].
Cholesterol-tagging therefore appears to be a general method,
applicable to many enveloped viruses.
We have recently shown that cholesterol tagging of an HRC
peptide from the paramyxovirus human parainfluenza virus type 3
(HPIV3) also increased its antiviral potency [43]. Notably, this
peptide maintained the ability of the unconjugated peptide to
inhibit both HPIV3 and the emerging paramyxoviruses Hendra
virus (HeV) and Nipah virus (NiV) [15,44], both fatal in humans.
The cholesterol-tagged peptide now acquired the ability to also
inhibit the rubulavirus SV5 (also known as PIV5) [43]. For Nipah
virus, the cholesterol-tagged HRC peptide was active in vivo,
effectively preventing and treating in an established animal model
what would otherwise be fatal Nipah virus encephalitis [45].
An additional advantage of cholesterol tagging is that it prolongs
the half-life of the peptide in vivo, through binding to serum
proteins. A pharmacokinetic (PK) study of C34-Chol in mice at
the concentration of 3.5 mg/kg showed that whereas unconjugat-
ed C34 was undetectable in plasma after 6 h, 130 nM of C34-
Chol was still detectable 24 h after the injection: a concentration
< 300-fold higher than the IC90 measured against multiple HIV-1
strains [38]. To further expand on the generality of our method to
potentiate the activity of natural HRC peptide inhibitors, we
assessed the value of dimerization of the fusion inhibitor. Several
examples of the successful use of multimerization to increase the
potency of fusion inhibitors [46,47] or entry inhibitors [48] have
been reported.
In the hypothesized avidity effect [49], dimerization/multi-
merization works by reducing the koff of the inhibitor-fusion
protein complex formation. Cholesterol tagging, on the other
hand, facilitates the encounter of the peptide with the viral target
protein by enriching the peptide in target membranes, an effect
which increases the kon for complex formation. The two
modifications could therefore work in concert, and both can be
implemented without any requirement for optimization of the
native sequence of the HRN/HRC peptide.
In the following, we report on our design of cholesterol-tagged
dimeric fusion inhibitors, and demonstrate their efficacy in
preventing or curtailing HPIV3, NiV, and HIV-1 replication
in vitro and in vivo.
Results
Design and Synthesis of the Cholesterol-containing
Branching Core
In designing a moiety containing the cholesterol group and the
branching functionalities we incorporated the features listed
below.
Firstly, we included a single cholesterol group. On one hand,
given the considerable reduction of solubility from the cholesterol
moiety, we wanted to avoid multiple copies of it; on the other
hand, we hypothesized that the balance of cholesterol to the
polypeptide moiety would still provide efficient anchoring of the
multimeric inhibitor to membrane rafts. A single anchoring moiety
is sufficient for proteins considerably larger in size [50] than even
large copy number multimeric inhibitors with a monomer size of
35–40 amino acids. Data published after our work was completed
lend further support to our hypothesis [51]. Moreover, we
envisage having only two copies of the inhibitor sequence, as
discussed below.
Secondly, we decided to focus on dimeric inhibitors. Findings by
Kay and co-workers suggest that despite the trimeric structure of
the fusion intermediate, the maximum benefit of multimerization
is achieved at the level of dimer, with little – or even no –
additional benefit in trimeric inhibitors [46,47].
Thirdly, we selected four polyethylene glycol (PEG) units as the
spacer between each monomer and the cholesterol core (Figure 1).
This would provide approximately the same distance between
monomers as that successfully used by Welch et al. [46]. Moreover,
we had found a PEG4 spacer between the peptide and cholesterol
to be beneficial in monomeric fusion inhibitors [45]. Notably, in a
subsequent publication Welch et al. showed that reduction of the
linker length provided considerable increase in potency [47]. This
is clearly an area that requires further exploration in our next-
generation branching cores.
Fourthly, we selected maleimide as a well-established chemo-
selective reactive moiety to conjugate the cholesterol-containing
core to the cysteine-containing peptide.
The structure of the cholesterol-containing dimeric core 9 is
shown in Figure 1. The compound is stable, and when stored at –
20uC it can be used reliably for at least 12 months.
Synthesis of Dimeric Cholesterol-tagged Fusion
Inhibitors
The peptides used in this study are listed in Table 1. The
dimeric cholesterol-tagged fusion inhibitors were prepared via
conjugation of the cysteine-containing peptide precursors (HPIV-
P1, HIV-P1) to the maleimide-functionalized core 9. We had
Cholesterol-Tagged Dimer Fusion Inhibitor Peptides
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we had done for the monomeric cholesterol-tagged inhibitors
[38,43,45]. The corresponding functionalized core was prepared
as described for 9 (see Figures S1 and S2), by using in the last step
bromoacetyl anhydride instead of 4-maleimido-butyric acid.
However, it turned out to be difficult to control the competition
between reactivity of the core with the peptide and hydrolysis of
the bromoacetyl group, leading to a difficult-to-separate mixture of
dimeric and momomeric/capped conjugates. Using maleimide
instead as the reactive moiety, the reaction was straightforward,
and it proceeded rapidly in good overall yield.
The Cholesterol-tagged Dimers Show Potent Antiviral
Activity Against Different Enveloped Viruses
We initially focused on HPIV3 and NiV. These viruses
represent major unmet medical needs [52,53], and our previous
finding that the HRC peptide derived from the sequence of
HPIV3 is effective on both HPIV3 and NiV [15,44] raised the
possibility of developing a single inhibitor for both. Moreover,
cholesterol-tagging of this peptide considerably improved its
antiviral potency on both viruses [43]. However, the cholesterol-
tagged inhibitor was not yet potent enough since it required
sequence optimization to display activity in vivo [45]. This
sequence therefore offered an ideal opportunity to test if
dimerization coupled to cholesterol-tagging could provide further
potency enhancement in comparison with cholesterol-tagging
alone.
We have recently shown that peptide efficacy in vivo is directly
correlated with inhibition of viral fusion and cell-to-cell spreading.
Peptide inhibitors able to inhibit viral entry but inefficient at
blocking cell-to-cell fusion were not effective in the natural host
[45,54]. Based on these data we decided to use a cell-to-cell fusion
assay using cells co-expressing the envelope viral glycoproteins of
HPIV3 (Figure 2) and NiV (Figure 3) which is our most stringent
in vitro assay to evaluate peptide efficacy Figure 2 shows a
Figure 1. Synthesis of the dimeric cholesterol-tagged fusion inhibitors via conjugation of a cysteine-containing peptide precursor
to the maleimide-functionalized core 9.
doi:10.1371/journal.pone.0036833.g001
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cholesterol-tagged monomer HPIV-P3 and the cholesterol-tagged
dimer HPIV-P4, derived from the same peptide sequence; for
comparison, we also show the fusion inhibitory activity of the
native, untagged peptide inhibitor HPIV-P2, and of a control
peptide dimerized via a PEG11 linker, HPIV-P5, similar to the one
used by Welch et al. [46].
The cholesterol-tagged dimer is considerably more potent than
the cholesterol-tagged monomer, which in turn is < 10-fold more
potent than the untagged inhibitor. Notably, in this case no
advantage is observed for dimerization alone, which exerts a
positive effect only in the presence of the cholesterol moiety.
Encouraged by these data, we tested the cholesterol-tagged
dimer for NiV: the HPIV3-derived HRC peptide is more active on
this virus [15,44]. Figure 3 shows a comparison of the fusion
inhibitory activity on NiV fusion of the monomeric fusion inhibitor
HPIV-P2 [44], the monomeric cholesterol-tagged inhibitor HPIV-
P3 [43], the dimeric inhibitor HPIV-P5, and the dimeric
cholesterol-tagged inhibitor HPIV-P4. Also in this case, the
dimeric-cholesterol tagged inhibitor is < 10-fold more potent
Table 1 Sequence of the peptides used in this study.
Peptide Sequence
HPIV-P1 Ac-VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI-GSGSG-C-NH2
HPIV-P2 Ac-VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI-GSGSG-C(CH2CONH2)-NH2
HPIV-P3 Ac-VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI-GSGSG-C(PEG4-Chol)-NH2
HPIV-P4 [(Ac-VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI-GSGSG-C(MAL-PEG4)]2-Chol
HPIV-P5 [(Ac-VALDPIDISIVLNKAKSDLEESKEWIRRSNGKLDSI-GSGSG-C(MAL-PEG11)]2-NH2
HIV-P1 Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-GSG-C-NH2
HIV-P2 Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-GSG-C(CH2CONH2)-NH2
HIV-P3 Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-GSG-C(PEG4-Chol)-NH2
HIV-P4 [(Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-GSG-C(MAL-PEG4)]2-Chol
HIV-P5 [(Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-GSG-C(MAL-PEG11)]2-NH2
doi:10.1371/journal.pone.0036833.t001
Figure 2. Inhibition of type 3 HPIV envelope glycoproteins mediated fusion by the HRC-derived fusion inhibitors HPIV-P2 (#), the
monomeric cholesterol-tagged fusion inhibitor HPIV-P3 (N), the dimeric fusion inhibitor HPIV-P5 (%), and the dimeric cholesterol-
tagged inhibitor HPIV-P4 (&). The percent inhibition of fusion (compared to control cells not treated with peptide) is shown as a function of the
(log-scale) concentration of peptide. The values are means (6SD) of the results from three experiments.
doi:10.1371/journal.pone.0036833.g002
Cholesterol-Tagged Dimer Fusion Inhibitor Peptides
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monomer and untagged dimer show similar (lower) potency.
In these experiments, there is progress from the native HRC
sequence to more and more potent inhibitors, without the need for
extensive sequence optimization. A relatively weak fusion inhibitor
(IC50.100 nM) is turned into a reasonably potent peptide (IC50
between 10–100 nM for HPIV3, between 1–10 nM for NiV) and
then into a potent inhibitor (IC50,10 nM for HPIV3,
IC50,1 nM for NiV).
We confirmed the in vitro efficacy using NiV live virus in plaque
reduction assays and we found that the IC50 values are
8.0260.66 nM for the cholesterol tagged monomer and
4.3661.3 nM for the cholesterol tagged dimer. As we have
previously shown for HPIV3 [45] the cholesterol tagged peptides
are highly effective at blocking viral entry and the increased
potency due to dimerization could be appreciated in the cell-to-cell
fusion assay of figure 2 and 3.
We then turned our attention to HIV-1. In this regard, we were
facing the opposite end of the spectrum in terms of potency
enhancement, since the native HRC peptide is already a potent
fusion inhibitor, and the potency of the cholesterol-tagged peptide
is in the picomolar range [38]. Moreover, access to the gp41
prehairpin intermediate appears to be sterically restricted, with
limited access to large proteins [55,56,57], which would eliminate
the potential beneficial effects of multimerization.
We compared the inhibitory activity on HIV-1 infectivity of the
untagged fusion inhibitor HIV-P2, the monomeric cholesterol-
tagged inhibitor HIV-P3 [38], the dimeric cholesterol-tagged
inhibitor HIV-P4, and the corresponding dimer without the
cholesterol tag, HIV-P5. Two strains of HIV-1 were used, the
CCR5 coreceptor-tropic (R5) strain BaL and the CXCR4
coreptor-tropic (X4) strain LAI/IIIB, as shown in Figure 4.
The cholesterol-tagged dimer is an extremely potent inhibitor of
both the IIIB and BaL strains, with IC50=2106370 pM and
10610 pM, respectively; the potency increase versus the untagged
HR-derived peptide is 150-fold and 6,000-fold on the two strains
(IC50 for HIV-P2=31.12636 nM and 60.14684 nM on IIIB and
BaL). The monomeric cholesterol-tagged inhibitor is comparably
potent, with IC50=80670 pM and 3606330 pM on IIIB and
BaL.
The comparable potency of the cholesterol-tagged monomer
and dimer suggest that we have reached the previously identified
potency plateau for very high-affinity inhibitors, where an increase
in the stability of the 6HB formed by the peptide does not translate
into higher antiviral potency [32,46,47]. Kay and co-workers have
shown that for inhibitors reaching beyond this threshold, the
extra-affinity can represent a ‘‘resistance capacitor’’, i.e. a reserve
of binding energy that counteracts the onset of resistance due to
affinity-disrupting mutations [46,47]. We are currently investigat-
ing whether this is the case for the cholesterol-tagged HIV dimeric
inhibitors.
The Cholesterol-tagged Dimer is Efficacious in vivo
Based on these data, we selected the HPIV/NiV inhibitor for in
vivo testing. We have previously shown that golden hamsters are a
suitable small animal model for NiV infection [45], since they
Figure 3. Inhibition of Nipah virus envelope glycoproteins
mediated fusion by the HPIV-3 HRC-derived fusion inhibitors
HPIV-P2(#),themonomericcholesterol-taggedfusioninhibitor
HPIV-P3 (N), the dimeric fusion inhibitor HPIV-P5 (%), and the
dimeric cholesterol-tagged inhibitor HPIV-P4 (&). The percent
inhibitionoffusion(comparedtocontrolcellsnottreatedwithpeptide)is
shownasafunctionofthe(log-scale)concentrationofpeptide.Thevalues
aremeans(6SD) ofthe resultsfromthreeexperiments.
doi:10.1371/journal.pone.0036833.g003
Figure 4. Inhibition of HIV infectivity by the fusion inhibitor HIV-P2 (&), the monomeric cholesterol-tagged inhibitor HIV-P3 (p), the
dimeric fusion inhibitor HIV-P5 (N), and the dimeric cholesterol-tagged inhibitor HIV-P4 (X). The efficiency of virus infection is shown as
relative luciferase units (RLU) as a function of the (log-scale) concentration of peptide.
doi:10.1371/journal.pone.0036833.g004
Cholesterol-Tagged Dimer Fusion Inhibitor Peptides
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disease, unlike the cat [58] or the ferret [59], which develop
primarily respiratory disease.
The efficacy of HPIV-P4 was investigated by administering the
peptide to golden hamsters intraperitoneally concurrently withvirus
infection,atthe doseof2 mg/kg.Injectionsofthepeptidewerethen
repeated every day for up to 14 days post-infection. Hamsters were
infected by intraperitoneal inoculation ofNiV, using 500x the LD50.
The infected hamsters were observed daily for clinical signs
(prostration, neurological signs) and variations in temperature and
weight. All the untreated animals were euthanized within 7 days
after infection due to neurological disease (Figure 5). Treatment
with the peptide resulted in survival of one of the five animals, while
the onset of the illness was considerably delayed in the other four,
leading to a significantly extended lifespan (Figure 5). This in vivo
activity provides the proof of concept for anti-viral efficacy of
dimerized, cholesterol-tagged peptides. Injection of the peptide in
theabsence ofviruschallengedidnotresultinanyapparenttoxicity,
with all the animals in the mock-infected group being healthy at the
end of the observation period (Figure 5).
Discussion
In conclusion, we have shown that dimerization of an HRC-
derived fusion inhibitory peptide in conjunction with cholesterol
tagging may be a general strategy for increasing its antiviral
potency in vitro, and that dimers can be effective in vivo. This
observation complements our previous reports on cholesterol-
tagging of fusion inhibitors [38,43,45,60,61].
We envisage several areas of improvement over the current
inhibitor series. Optimization of the length of the linker joining the
monomers may provide considerable increase in potency [49], as
specifically demonstrated for HIV by the work of Kay and co-
workers [47]. Using the synthetic scheme shown in Figures S1, S2,
maleimide-functionalized cores with PEG spacers of different
length can be easily prepared, and they can all be reacted with the
same precursor to rapidly select the most potent inhibitor. Also,
although we focused on dimeric peptides, trimeric or higher copy
number cores may provide an advantage, especially when the
starting HRC inhibitor is weak. Finally, other chemoselective pairs
may prove superior in terms of reactivity and yield over the
maleimide-cysteine pair. It should be noted however, that the
latter pair offers a safety advantage, since it is featured in an
antibody-drug conjugate recently approved for human use
(ADCETRISH, Seattle Genetics).
At this stage, cholesterol-tagging and dimerization represent
feasible strategies for boosting the inhibitory potency to levels
that, in some cases, may be compatible with in vivo use, without
the need for extensive sequence optimization. With the
availability of the necessary building blocks, synthesis of
cholesterol-tagged monomers and dimers is easily and rapidly
accomplished from the same precursor peptide. As such, this
strategy may contribute to emergency responses to outbreaks of
existing or novel viruses. The activity in vivo of a dimeric
cholesterol-tagged inhibitor of NiV supports the potential utility
of this strategy. We are currently exploring the scope of this
approach on several enveloped viruses.
Materials and Methods
Synthesis
The synthesis of the cholesterol-containing branching core
[Mal-PEG4]2-Chol (9) is detailed in the Figures S1 and S2. The
synthesis of peptides HPIV-P1, HPIV-P2, HPIV-P3, HIV-P1,
HIV-P2, and HIV-P3 (Table 1) has already been described
[38,43]. Chemoselective conjugation between the Cys-peptide
precursors HPIV-P1 and HIV-P1 and the cholesterol derivative 9,
to yield conjugates HPIV-P4 and HIV-P4 (Table 1) is detailed in
the Figures S1 and S2.
Virus
Nipah virus (isolate UMMC1; GenBank AY029767) [62] was
prepared on Vero-E6 cells as described previously [63] in biosafety
level 4 (BSL-4) laboratory Jean Merieux in Lyon, France.
Figure 5. In vivo efficacy of the dimeric cholesterol-tagged peptide. HPIV-P4 (N) was given intraperitoneally to groups of 5 hamsters
concurrently with live NiV infection. Injections of the inhibitor were then repeated every day for up to 10 days post infection. Control animals were
injected with vehicle alone (untreated, %) or with peptide without NiV infection (mock infected, D). Treatment with the dimeric cholesterol tagged
peptide led to a statistically significant increase of survival compared to non treated infected animals (Chi
2 test=**P value=0.008).
doi:10.1371/journal.pone.0036833.g005
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The assays to measure Peptide inhibition of viral entry or viral
infectivity were performed as previously described [38,43,45]. A
brief description of the assays is given below.
Antiviral activity against live Nipah virus. In the plaque
reduction assay, serial dilutions of peptides in Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) were added to reporter cell
monolayers of Vero E6 cells (in 12well-plates, 5.10
5 cells/well) for
1h at 37uC, 5% CO2. Then, 200 pfus of NiV were added to the
supernatant of the Vero cells and incubated for 1h at 37uC.
Supernatants were then replaced by 2ml of 1.6% of Carboxymeth-
ylcellulose in DMEM containing 3% of FCS. Plates were incubated
for 4 days at 37uC, 5% CO2. Plates were finally revealed as a classic
centralplaqueassay,aspreviouslydescribed inGuillaumeetal2004
(REF).IC50werecalculated usingGraphPadPrism4software.Data
were expressed as mean6standard deviation (SD).
Antiviral activity against HIV-1 in TZM-bl cells. The
TZM-bl cell line is an epithelial HeLa-derived cell line engineered
to express CD4, CCR5, CXCR4 and integrated reporter genes for
firefly luciferase (Luc) and E.coli b-gal under the control of an
HIV-1 LTR that is transactivated by the Tat protein synthesized
after infection [4]. Cells were seeded into 96-well flat bottomed
plastic plates (Falcon, Becton Dickinson Labware, Lincoln Park,
NJ) at 1610
4 cells/well and were incubated in the presence or
absence of the compounds at 37uC for 1 h in a total volume of
50 ml. Aliquots of CCR5-dependent (R5) HIV-1Bal or CXCR4-
dependent (X4) HIV-1LAI/IIIB viral stocks at the multiplicity of
infection (moi) of 4 were then added to a total volume of 100 mli n
culture medium containing 15 mg/ml DEAE-dextran (Sigma-
Aldrich, St. Louis, MO). Forty-eight h later, the efficiency of virus
infection was determined as relative Luc units (RLU) by Luciferase
assay system (Promega, Madison, WI).
Antiviral activity against HIV-1 in activated peripheral
blood mononuclear cells (PBMC). PBMC were isolated from
blood obtained at the New York Blood Center, then cultured in
RPMI 1640 supplemented with 10% FBS, 10 mM L-glutamine
(Cellgro), and 100 U/ml IL-2 (ARRRP, contributed by Hoffman-
LaRoche, Inc - Culture Medium). Half the PBMC culture was
stimulated with 5 mg/ml of phytohemagglutinin (PHA; Sigma, St.
Louis, MO), half with an anti-CD3 mAb (supernatant from the
OKT3 hybridoma) in Culture Medium, directly after isolation.
After 3 days, the differently stimulated cells were mixed in equal
proportions, washed, and suspended in Culture Medium supple-
mented with 100 mg/ml of penicillin/streptomycin for the
remainder of the culture. The PBMC were seeded at 1.4610
6
cells/ml in 100 ml per well in 96-well plates before addition of a
serially diluted inhibitor immediately prior to inoculation with the
test virus. HIV-1 replication was measured using an in-house p24
Gag antigen ELISA after 7 days of culture. Residual p24 Gag from
the input virus in 4 replicates per assay was measured and
subtracted. Net p24 Gag production in the test wells was
compared with that in the control wells (no inhibitor in 12
replicates/assay, defined as 100%). The inhibitors were titrated in
5-fold steps and each culture well, mixed cells and supernatant,
was analyzed. Two assay replicates per condition were combined
in the ELISA, e.g. 12 assay 100% viral growth control wells (see
above) were combined to 6 ELISA wells.
Beta-galactosidase Complementation-based Fusion
Assay
We adapted an assay [64] that detects early stages of fusion
activation, since the read-out does not depend upon downstream
transactivation events. We used this assay for experiments in which
the greater range of detection of this assay was necessary. The
assay is based on alpha complementation of beta-gal; the beta-gal
protein lacking the N-terminal 85 residues (omega peptide) is
expressed from one plasmid, and the N-terminal 85 residues (alpha
peptide) is expressed from a second plasmid. Cell fusion leads to
complementation, and beta-galactosidase is quantitated using the
Galacto-Star (Applied Biosystems) chemiluminescent reporter
gene assay system. Receptor bearing cells expressing the omega
peptide are mixed with viral glycoproteins co-expressing cells that
also express the alpha peptide, at various temperatures and at
specific time points. Fusion is stopped by lysing the cells with lysis
buffer. Fusion inhibitory peptides are added when the two set of
cells are mixed together.
Golden Hamster Infection
Eight-week-old golden hamsters (Mesocricetus auratus, Janvier,
France) were anesthetized and infected intraperitoneally (i.p.) with
0.4 mL of NiV in a BSL-4 laboratory. Groups of 5 animals were
treated daily by i.p injections of peptide (2 mg/kg) for 10 days,
starting from the day of infection, or left untreated. The animals
were followed daily for 3 weeks. For comparison of survival curves,
Chi
2 analysis was performed using test using Graph Pad Prism4
program.
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